Neuropathy News and Research RSS Feed - Neuropathy News and Research

Study finds South Africans living with HIV more resilient despite chronic pain

Study finds South Africans living with HIV more resilient despite chronic pain

When one thinks about chronic conditions that are commonly painful, HIV doesn't typically spring to mind. However, more than 50% of HIV-positive individuals experience a painful condition like headache, chest pain or neuropathy, and that pain is frequently experienced as moderate to severe in intensity. [More]
New dermatological treatment could potentially help prevent or reverse diabetic neuropathy

New dermatological treatment could potentially help prevent or reverse diabetic neuropathy

For the 25 percent of type-2 diabetes patients who suffer from numbness and extreme nerve pain in their feet, a new dermatological treatment being tested by Northwestern Medicine scientists could potentially help prevent and maybe even reverse the neuropathy. [More]
Study finds tight glycemic control provides no impact on patient-important microvascular outcomes

Study finds tight glycemic control provides no impact on patient-important microvascular outcomes

The glucocentric focus on lowering blood sugar in Type 2 diabetes may have short-circuited development of new diabetes therapies, according to a new paper published by Mayo Clinic researchers in the journal Circulation: Cardiovascular Quality and Outcomes. [More]
Scientists report new neurological complication from Zika virus infection

Scientists report new neurological complication from Zika virus infection

Dr. John England, Professor and Chair of Neurology at LSU Health New Orleans School of Medicine, and colleagues in Honduras and Venezuela have reported a new neurological complication of infection with the Zika virus. [More]
MDI Biological Laboratory receives NIH grant for research on peripheral neuropathy

MDI Biological Laboratory receives NIH grant for research on peripheral neuropathy

The MDI Biological Laboratory has announced that it has received a grant of $456,500 over two years from the National Institutes of Health for the study of peripheral neuropathy. [More]
Scientists unravel effect of prion proteins on the nerves

Scientists unravel effect of prion proteins on the nerves

Ever since the prion gene was discovered in 1985, its role and biological impact on the neurons has remained a mystery. [More]
Neuropathic pain could be significantly reduced by targeting brain cells

Neuropathic pain could be significantly reduced by targeting brain cells

Neuropathic pain - which affects more than 1 million Americans - could be reduced or even eliminated by targeting brain cells that are supposed to provide immunity but, in some instances, do the opposite, causing chronic pain that could last a lifetime. [More]
Scientists uncover genetic cause of rare pediatric progressive neuropathy

Scientists uncover genetic cause of rare pediatric progressive neuropathy

Researchers from the National Institutes of Health and their colleagues identified the genetic cause and a possible therapeutic target for a rare form of pediatric progressive neuropathy. [More]
Neurologists identify cause of immune-mediated neuropathies

Neurologists identify cause of immune-mediated neuropathies

Würzburg neurologists have discovered an antibody that is involved in triggering certain forms of neuropathies. This discovery also allowed them to show a way to treat these diseases successfully. [More]
Research findings elucidate how neurons process, represent touch in rat and the human brain

Research findings elucidate how neurons process, represent touch in rat and the human brain

When reaching into a pocket or purse, it is easy to use the sense of touch to distinguish keys from loose change. Our brains seamlessly integrate the tactile, sensory cues from our fingers with hand movements to perceive the different objects. [More]
USPTO grants key patent for Quark Pharmaceuticals' QPI-1007 ocular neuroprotectant

USPTO grants key patent for Quark Pharmaceuticals' QPI-1007 ocular neuroprotectant

Quark Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office has granted a key patent covering the treatment of patients suffering from non-arteritic anterior ischemic optic neuropathy ("NAION") with the Company's ocular neuroprotectant QPI-1007. [More]
Experts recommend several measures to reduce firearm suicide rates in the U.S.

Experts recommend several measures to reduce firearm suicide rates in the U.S.

Researchers from Columbia University Medical Center nd New York State Psychiatric Institute have found that legislation reducing access to firearms has lowered firearm suicide rates in other countries. [More]
FDA approves safety labeling changes for fluoroquinolone antibiotics

FDA approves safety labeling changes for fluoroquinolone antibiotics

The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections. [More]
Duke to lead early-stage clinical trials for promising new neurological therapies

Duke to lead early-stage clinical trials for promising new neurological therapies

Duke University could receive up to $19 million to lead early-stage clinical trials for new drugs to treat neurological conditions such as Alzheimer's disease and neuropathy. [More]
Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Five-year survival data published online today in Blood, the Journal of the American Society of Hematology, suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease has persisted despite receiving previous therapies. [More]
European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year. [More]
Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, both investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of hereditary TTR-mediated amyloidosis (hATTR amyloidosis). [More]
Argentine Tango dance holds potential to reduce fall risk among cancer survivors with neuropathy

Argentine Tango dance holds potential to reduce fall risk among cancer survivors with neuropathy

Dance as a form of therapy - specifically Argentine Tango -- has the potential to significantly improve balance and reduce falls risk among cancer patients experiencing peripheral neuropathy, according to new research conducted by a multidisciplinary research team at The Ohio State University. [More]
Risk of blindness from spinal-fusion surgery has declined, study shows

Risk of blindness from spinal-fusion surgery has declined, study shows

The risk of blindness caused by spinal fusion, one of the most common surgeries performed in the U.S., has dropped almost three-fold since the late 1990s, according to the largest study of the topic to date. [More]
Transorbital ACS can improve vision in patients with glaucoma, optic nerve damage

Transorbital ACS can improve vision in patients with glaucoma, optic nerve damage

Vision loss due to glaucoma or optic nerve damage is generally considered irreversible. Now a new prospective, randomized, multi-center clinical trial demonstrates significant vision improvement in partially blind patients after 10 days of noninvasive, transorbital alternating current stimulation. [More]
Advertisement
Advertisement